EIF2AK4 and cancer: Perturbing the translational quality control by manipulating the GCN2-ISR has emerged as a therapeutic strategy in combination treatment with asparaginase (ASNase), an enzyme that depletes asparagine and glutamine, in acute lymphoblastic leukemia, highlighting the potential for GCN2 inhibitors (GCN2i) such as GCN2-IN-1, GCN2-IN-6, and GCN2iB in amino acid dependencies in cancer (44, 45).